Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + dexamethasone for untreated multiple myeloma with renal impairment
ACTRN12611000605998Phase 2Recruiting
- Sponsor
- Prof. Andrew Spencer
- Start
- Apr 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Prof. Andrew Spencer. Primary endpoint: Renal response and reversal of renal impairment. Started Apr 2011; status: recruiting.
02
Drugs
bortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12611000605998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000605998.